

[illegible]

seq_name: /SIPSL/gcdata/geneseq/genbseqn-emb1/NA1999.DAT.AA238150

seq_documentation_block:

ID AA238150 standard; DNA: 6951 BP.

XX AC

XX AA238150;

XX 22-FEB-2000 (first entry)

XX

XX Human C3b/C4b receptor (CRI) protein encoding DNA.

DE

XX C3b/C4b receptor; CRI protein; cell-surface protein; erythrocyte; human;

XX complement regulatory activity; complement pathway enzyme; tissue damage;

KM reperfusion injury; Arthus reaction; myocardial infarct; inflammation;

KM heart condition; autoimmune disorder; diagnostic; ss.

XX

OS Homo sapiens.

XX

XX PN US5981481-A.

XX

XX 09-NOV-1999.

XX

XX 06-JUN-1995; 95US-0470652.

XX PF

XX 03-APR-1989; 89US-0332865.

PR 06-DEC-1974; 74US-0350238.

PR 24-FEB-1993; 93US-0026134.

PR 01-APR-1988; 88US-0176532.

XX

PA (UYJO) UNIV JOHNS HOPKINS.

PA (BGHM) BRIGHAM & WOMENS HOSPITAL.

PA (AVAN-) AVANT IMMUNOTHERAPEUTICS INC.

PI

PI Concino MF, Wong WM, Makrides SC, Klickstein LB, Fearon DT, Ip SH;

PI Marsh HC, Carson GR;

XX

XX WPI; 1999-633357/54.

DR P-PSDB; AAY55751.

XX

XX A human C3b/C4b receptor (CRI) protein having antinflammatory and

PT cardiant activity -

PS

PS Disclosure; Fig 1A-P; 87pp; English.

XX

XX The invention relates to a human C3b/C4b receptor (CRI) protein. The CRI

CC protein or fragment is expressed as a cell-surface protein on the surface

CC of a non-human cell and exhibits a complement regulatory activity of full

CC -length human CRI as expressed on erythrocytes. The CRI function in vivo

CC may be mediated through the inhibition of complement pathway enzymes. The

CC soluble CRI protein exhibits a complement regulatory activity, and this

CC may be used to prevent reperfusion injury, inhibit Arthus reaction, and

CC neutrophil mediated tissue damage, and reduce myocardial infarct size,

CC and inflammation. The CRI protein and its fragments can also be used in

CC the treatment of conditions which involve unwanted complement activity,

CC e.g. shock lung, tissue damage due to burn, or ischemic heart conditions,

CC and autoimmune disorders. CRI proteins, analogues, derivatives, and anti

CC -CRI antibodies are used in assays, and diagnostics. The present sequence

CC represents a DNA encoding the human CRI protein.

XX

SQ Sequence 6951 BP; 1802 A; 1680 C; 1661 G; 1808 T; 0 other;

alignment_scores:

Quality: 649.50 Length: 148
 Ratio: 4.883 Gaps: 2
 Percent Similarity: 89.865 Percent Identity: 81.757

alignment_block:

US-10-031-904-8 x AA158380 ..
 Align seg 1/1 to: AA158380 from: 1 to: 6951

```

10 ProPheProSerAArgPhe.....ProGlyLeuLeuAlaAla 24
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
70 CCGGCGCCCGGCTCCCTTCCTGCTGCGAGAGATCCCTGCTGCGGCTTGT 119
24 uValLeuLeu...LeuSerSerPheSerAspGlnCysAsnValProGluT 40
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
120 GGTGCTGCTTGGCGTCCGCGTGGCTGGGCTCAATGCAATGCCAGAAAT 169
40 rPheProPheAlaArgProThrAsnLeuThrAspAspPheGluPhePro 56
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
170 GGTTCATTCATTCGCGGCTTACCACTAAGTATGATGAGTTGATTCCTCC 219
57 lIleGlyThrTyrLeuAsnTyrGlnCysArgProGlyTyrSerGlyArgPr 73
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
220 ATTTGGACATATCTGAATCATATGATGCGCCCTGTTATTCGGAGAGACC 269
73 oPheSerlIleCysLeuLysAsnSerValTrpThrSerAlaLysAspL 90
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
270 GTTTTCTATCATCTGCTTAAAAAACTAGTGTGAGTGTGCTAGAGACA 319
90 yScysLysArgLysSerCysArgAsnProProAspProValAsnGlyMet 106
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
320 GGTGCGAGACTAATCATATGCTTAATCTCCAGATCCCTGTGATGCGATG 369
107 AlaAlaValIleLysAspIleGlnPheGlySerGlnIleLysTyrSerCy 123
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
370 GTGCATGATGATCAAGGATCCAGTTCGATCCCAATTAATTAATTCCTG 419
123 sProLysGlyTyrArgLeuIleGlySerSerSerAlaThrCysIleIle 140
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
420 TACTTAAGGATACCGACTATGCTGCTGCTCCACATGATCATCATCT 469
140 eGcLysAnThrValIleTrpAspAsnLysThrProValCysAsp 154
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
470 CAGGTGATGATCTGATATTTGGATTAATGAACACTAATTTGTCAC 513

```

seq_name: /SIDSL/gcdata/geneseq/geneseqn-emb1/AA2001A.DAT:AA158380

seq_documentation_block:

1D AA158380 standard; cDNA; 7313 BP.

AC AA158380;

DF 32-OCT-2001 (first entry)

DE Human polynucleotide SEQ ID NO 583.

KM Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
 KM peripheral nervous system; neuropathy; central nervous system; CNS;
 KM Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 KM amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
 KM chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 KM leukaemia; ss.

OS Homo sapiens.

PN WO200153312-11.

XX 26-JUL-2001.

PF 26-DEC-2000; 2000WO-US34263.

PR 21-JAN-2000; 2000US-0488725.
 PR 25-APR-2000; 2000US-0552317.
 PR 09-JUL-2000; 2000US-0598042.
 PR 19-JUL-2000; 2000US-0620312.
 PR 03-AUG-2000; 2000US-0653450.
 PR 14-SEP-2000; 2000US-0662191.
 PR 19-OCT-2000; 2000US-0693036.
 PR 29-NOV-2000; 2000US-0727344.

(HYSE-) HXSEQ INC.

XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 PI Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
 PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;

DR WI: 2001-44253/47.
 DR P-ASDB; AAM39224.

PT Novel nucleic acids and polypeptides, useful for treating disorders
 PT such as central nervous system injuries -

PS Claim In SEQ ID NO 583; 10078bp; English.

CC The invention relates to human nucleic acids (AA157798-AA161369) and
 CC the encoded polypeptides (AAM38642-AA42213) with nootropic,
 CC immunosuppressant and cytostatic activity. The polynucleotides are useful
 CC in gene therapy. A composition containing a polypeptide or polynucleotide
 CC of the invention may be used to treat diseases of the peripheral nervous
 CC system, such as peripheral nervous injuries, peripheral neuropathy and
 CC localised neuropathies and central nervous system diseases, such as
 CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
 CC utilisation of the activities such as: immune system suppression,
 CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
 CC assays for receptor activity, arthritis and inflammation, leukaemia and
 CC C.N.S disorders.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification.

SQ Sequence 7313 BP; 1903 A; 1770 C; 1733 G; 1907 T; 0 other;

alignment_scores:

Quality: 649.50 Length: 148
 Ratio: 4.883 Gaps: 2
 Percent Similarity: 89.865 Percent Identity: 81.757

alignment_block:

US-10-031-904-8 x AA158380 ..

Align seg 1/1 to: AA158380 from: 1 to: 7313

```

10 ProPheProSerAArgPhe.....ProGlyLeuLeuAlaAla 24
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
70 CCGGCGCCCGGCTCCCTTCCTGCTGCGAGAGATCCCTGCTGCGGCTTGT 119
24 uValLeuLeu...LeuSerSerPheSerAspGlnCysAsnValProGluT 40
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
120 GGTGCTGCTTGGCGTCCGCGTGGCTGGGCTCAATGCAATGCCAGAAAT 169
40 rPheProPheAlaArgProThrAsnLeuThrAspAspPheGluPhePro 56
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
170 GGTTCATTCATTCGCGGCTTACCACTAAGTATGATGAGTTGATTCCTCC 219
57 lIleGlyThrTyrLeuAsnTyrGlnCysArgProGlyTyrSerGlyArgPr 73
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
220 ATTTGGACATATCTGAATCATATGATGCGCCCTGTTATTCGGAGAGACC 269
73 oPheSerlIleCysLeuLysAsnSerValTrpThrSerAlaLysAspL 90
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
270 GTTTTCTATCATCTGCTTAAAAAACTAGTGTGAGTGTGCTAGAGACA 319

```


20	LeuLeuAlaAlaLeuValLeuLeu...LeuSerSerPheSerAspGlnCys	35
6	CHeCGTGGCGGTGTGGTGCTGCTGCCTGCCGCTGGCTGGGTCATAG	55
35	sAsnValProGluTrpLeuProPheAlaArgProThaAsnLeuthrAspa	52
56	CAATGCCCCAGAAATGGCTCCATTGGCAGGCGCTACCAACTAATCATGATG	1050
52	sPhelglnPheProIleGlyThrTrpTleAsnAntyPrGluGlyArgProGly	68
106	AGTTTGAGTTTCCCATTGGGACAATATCGAACATAAGAATGCCGCCCGGT	1550
69	TyrSergLysArgProPheSerIleIleCysLeuLysAsnSeValTrpTh	85
156	TATTATGGAGAAGCCGTTTTCTATCATCTCGCTAAAAAACTCACGCTGGAC	2050
85	rSerAlaLysAspLysCysLysArgLysSerCysArgAsnProFoaSp	1020
206	TGGTGTAAAGGAAGGTGACAGACGTAATATCATGTCTGATCTCCAATC	2550
102	rovalAsnGlnMetLahHisValIleLysAspIleGlnPheGlySerGln	1180
256	CHeTGAATGGCATGGTGGCATGTGATCAAAGACATCCAAATTGGATCCCA	3050
119	IleLysTySerCysProLysGlyTyrArgLeuIleGlySerSerSerAl	1350
306	ATTAATATTCTTGTACATAAAGATACCAGCATCATGGTCTCCTGCTGCG	3550
135	aThrCysIleIleSerGlyAsnThrValIleTrpAspAsnLysThrProv	1550
356	CAATTCATCATCTCAGGAGATACGTGCTATTGGATATATGAACACCTTA	4050

rs ::

1

406 TTGTGAC 413